Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.39 |
| ▸ | ILK | Q13418 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.36 |
| ▸ | GAK | O14976 | 3/20 | 0.36 |
| ▸ | FBP1 | P09467 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1849319 | 0.81 | HPGDS (0.53) | EGFRPIK3CAMTORHPGDS | |
| SCHEMBL12466486 | 0.79 | MAPT (0.49) | EGFRILKPIK3CAGAKFBP1 | |
| SCHEMBL24838191 | 0.77 | DPP4 (0.44) | EGFRILKGAKFBP1ALDH1A1 | |
| SCHEMBL25603205 | 0.77 | EGFR (0.37) | EGFRILKPIK3CAMTORGAK | |
| SCHEMBL14486650 | 0.74 | PDGFRB (0.46) | EGFRHPGDSPDGFRBPDGFRATRPA1 | |
| SCHEMBL14485979 | 0.74 | GRM5 (0.47) | EGFRPIK3CAPDGFRBPDGFRAPIK3CG | |
| SCHEMBL30150429 | 0.73 | SYK (0.33) | EGFRFBP1 | |
| SCHEMBL20659404 | 0.73 | SYK (0.33) | EGFRFBP1 | |
| SCHEMBL14486328 | 0.72 | PDGFRB (0.47) | PDGFRBPDGFRA | |
| SCHEMBL14486066 | 0.72 | GRM5 (0.55) | EGFRALDH1A1HPGDSPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2729449-B1 | 5- OR 6 - SUBSTITUTED 3 - HYDROXY - 2 ( 1H) - PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAIN | TAKEDA PHARMACEUTICALS CO (JP) | 2017-10-18 | — | — | EP | disclosed |
| EP-2729449-B1 | 5- OR 6 - SUBSTITUTED 3 - HYDROXY - 2 ( 1H) - PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAIN | TAKEDA PHARMACEUTICALS CO (JP) | 2017-10-18 | — | — | EP | disclosed |
| US-9180122-B2 | 5- or 6-substituted 3-hydroxy-2 (1 H)-pyridinones as D-amino acid oxidase (DAAO) inhibitors in therapy of diseases such as schizophrenia, cognitive disorder and pain | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-10 | — | — | US | disclosed |
| US-9180122-B2 | 5- or 6-substituted 3-hydroxy-2 (1 H)-pyridinones as D-amino acid oxidase (DAAO) inhibitors in therapy of diseases such as schizophrenia, cognitive disorder and pain | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-10 | — | — | US | disclosed |
| US-9180122-B2 | 5- or 6-substituted 3-hydroxy-2 (1 H)-pyridinones as D-amino acid oxidase (DAAO) inhibitors in therapy of diseases such as schizophrenia, cognitive disorder and pain | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20140243353-A1 | 5- OR 6-SUBSTITUTED 3-HYDROXY-2(1H)-PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140243353-A1 | 5- OR 6-SUBSTITUTED 3-HYDROXY-2(1H)-PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140243353-A1 | 5- OR 6-SUBSTITUTED 3-HYDROXY-2(1H)-PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
| EP-2729449-A1 | 5- OR 6 - SUBSTITUTED 3 - HYDROXY - 2 ( 1H) - PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAIN | Takeda Pharmaceutical Company Limited (JP) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013004996-A1 | 5- OR 6 - SUBSTITUTED 3 - HYDROXY - 2 ( 1H) - PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAIN | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-10 | — | — | WO | disclosed |
| WO-2013004996-A1 | 5- OR 6 - SUBSTITUTED 3 - HYDROXY - 2 ( 1H) - PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAIN | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-10 | — | — | WO | disclosed |
| EP-2488511-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011041634-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011041634-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | WO | disclosed |
| US-20110081316-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110081316-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110081316-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243353-A1 | 5- OR 6-SUBSTITUTED 3-HYDROXY-2(1H)-PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAID | DAO, DDO, HAO1 | EGFR 2414/4885ILK 4641/4885PIK3CA 2214/4885 |
| US-20110081316-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIK3CG | EGFR 1370/4885ILK 1282/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.